Skip to main content
. Author manuscript; available in PMC: 2013 Mar 14.
Published in final edited form as: Dalton Trans. 2012 Jan 26;41(10):3046–3052. doi: 10.1039/c2dt11811d

Table 4.

IC50 values for SK-hep-1 and HCT-15 human cancer cells for molecular rectangles 1–8, donors, cisplatin and dxorubicin.

compound IC50 µM[a]
SK-hep-1 HCT-15
1 >200 >200
2 >200 >200
3 6.97±0.69 7.46±0.24
4 29.53±1.72 39.45±1.73
5 66.19±0.25 53.66±0.27
6 63.58±1.27 57.05±0.98
7 9.60±0.84 10.66±0.19
8 16.32±1.98 17.68±0.92
D1 >200 >200
D2 >200 >200
cisplatin 12.38±0.24 8.38±2.31
doxorubicin 2.67±0.24 15.34±0.58
[a]

IC50: drug concentration necessary for 50% inhibition of cell viability.